NPI is a privately held company located in Beverly, MA. It has a proprietary technology for producing paclitaxel from yew trees. The company has proven production capabilities and a substantial supply of yew trees. NPI will use this additional capital to accelerate the expansion of its production capabilities.

"We are very pleased to be extending our relationship with NPI, particularly in light of the growing body of evidence that paclitaxel appears to be a safe and effective treatment for coronary artery disease," said Fred Colen, Senior Vice President and Chief Technology Officer of Boston Scientific. "NPI is committed to ensuring that a supply of paclitaxel is available to us well into the future. We look forward to continuing what has been a cooperative and fruitful relationship."

Boston Scientific has acquired worldwide co-exclusive rights from Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSE: ANP) to use paclitaxel to coat its coronary stent products and other vascular and non-vascular products. Angiotech Pharmaceuticals is a Canadian pharmaceutical company dedicated to the development of medical coatings and treatments for chronic inflammatory diseases through reformulation of paclitaxel.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The Company's products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.